Waltham, MA
Akaza Research announced the release of OpenClinica 3.0, the newest version of the open source electronic data capture (EDC) software for clinical trials. This latest production release adds a host of new capabilities designed to further accelerate the adoption of open source into mainstream research.
“We have added powerful new capabilities and made them accessible through an intelligent, task-oriented user interface," said Cal Collins, CEO of Akaza Research.
Key features of OpenClinica 3.0 include: streamlined user interface that simplifies site usage, study progress dashboard, improved query workflows, with notifications, chain of custody, and task management, source data verification workspace, faster page load time, dedicated Study Build module, improved control over significant digits in eCRF data items, job scheduler and web services interface to allow for programmatic data interchange with other systems
As open source software, OpenClinica is free for organizations to use and modify. The software may be downloaded here. Akaza Research will be conducting a webinar presentation of OpenClinica 3.0 on October 28, 2009 to demonstrate the new product and answer questions form the community, click here for information.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.